Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiron Diagnostics' ACS:180 BR

This article was originally published in The Gray Sheet

Executive Summary

Firm gains 510(k) clearance for expanded labeling to allow marketing of the in vitro cancer antigen CA 27.29 test for use as an aid in monitoring patients previously treated for Stage II or Stage III breast cancer. The firm's original August 1997 clearance covers use as an aid in managing breast cancer patients with metastatic disease by monitoring progression or regression in response to treatment. Data used to support the expanded indication included 942 serial specimens from 162 patients
UsernamePublicRestriction

Register

MT009921

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel